Altrinsic Global Advisors LLC Fate Therapeutics Inc Transaction History

Altrinsic Global Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $801,090 - $1.63 Million	-27,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $177,810 - $287,190	-3,000 Reduced 10.0%	27,000 $1.6 Million
Q1 2021 May 14, 2021	SELL	$72.16 - $117.4 $721,600 - $1.17 Million	-10,000 Reduced 25.0%	30,000 $2.47 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $761,800 - $2.02 Million	-20,000 Reduced 33.33%	40,000 $3.64 Million
Q1 2020 May 14, 2020	SELL	$17.28 - $31.88 $172,800 - $318,800	-10,000 Reduced 14.29%	60,000 $1.33 Million
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $175,000 - $325,800	20,000 Added 40.0%	70,000 $1.14 Million
Q2 2018 Aug 13, 2018	BUY	$9.16 - $13.48 $458,000 - $674,000	50,000 New	50,000 $567,000

174

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $202M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Altrinsic Global Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Altrinsic Global Advisors LLC with notifications on news.